LIPOCINE INC(NASDAQ:LPCN) stock Fundamental Analysis

Fundamental Rating

Overall LPCN gets a fundamental rating of 5 out of 10. We evaluated LPCN against 198 industry peers in the Pharmaceuticals industry. LPCN has a great financial health rating, but its profitability evaluates not so good. LPCN is valued quite expensively, but it does show have an excellent growth rating.

Quickly go to:

1. Profitability

1.1 Basic Checks

LPCN had positive earnings in the past year.

In the past year LPCN has reported a negative cash flow from operations.

In the past 5 years LPCN reported 4 times negative net income.

In the past 5 years LPCN always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of LPCN (0.04%) is better than 82.83% of its industry peers.

LPCN has a Return On Equity of 0.04%. This is amongst the best in the industry. LPCN outperforms 83.33% of its industry peers.

		Industry Rank	Sector Rank
ROA	0.04%
ROE	0.04%
ROIC	N/A

ROA(3y)-33.24%

ROA(5y)-36.72%

ROE(3y)-36.81%

ROE(5y)-49.69%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Profit Margin value of 0.08%, LPCN belongs to the best of the industry, outperforming 82.83% of the companies in the same industry.

The Operating Margin and Gross Margin are not available for LPCN so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	0.08%
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

LPCN does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for LPCN has been increased compared to 1 year ago.

Compared to 5 years ago, LPCN has more shares outstanding

There is no outstanding debt for LPCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -4.24, we must say that LPCN is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -4.24, LPCN perfoms like the industry average, outperforming 40.40% of the companies in the same industry.

There is no outstanding debt for LPCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-4.24

ROIC/WACCN/A

WACC9.66%

2.3 Liquidity

A Current Ratio of 14.75 indicates that LPCN has no problem at all paying its short term obligations.

With an excellent Current ratio value of 14.75, LPCN belongs to the best of the industry, outperforming 89.39% of the companies in the same industry.

A Quick Ratio of 14.75 indicates that LPCN has no problem at all paying its short term obligations.

LPCN has a Quick ratio of 14.75. This is amongst the best in the industry. LPCN outperforms 89.39% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	14.75
Quick Ratio	14.75

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

LPCN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 150.49%, which is quite impressive.

The Earnings Per Share has been growing by 213.46% on average over the past years. This is a very strong growth

LPCN shows a strong growth in Revenue. In the last year, the Revenue has grown by 492.40%.

Measured over the past years, LPCN shows a very strong growth in Revenue. The Revenue has been growing by 133.89% on average per year.

EPS 1Y (TTM)150.49%

EPS 3Y213.46%

EPS 5YN/A

EPS Q2Q%542.86%

Revenue 1Y (TTM)492.4%

Revenue growth 3Y-11.47%

Revenue growth 5Y133.89%

Sales Q2Q%1514.78%

3.2 Future

Based on estimates for the next years, LPCN will show a very negative growth in Earnings Per Share. The EPS will decrease by -39.74% on average per year.

LPCN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.92% yearly.

EPS Next Y-222.53%

EPS Next 2Y-72.06%

EPS Next 3Y-39.74%

EPS Next 5YN/A

Revenue Next Year-85.43%

Revenue Next 2Y-68.57%

Revenue Next 3Y-47.42%

Revenue Next 5Y37.92%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 2.11 indicates a rather cheap valuation of LPCN.

Compared to the rest of the industry, the Price/Earnings ratio of LPCN indicates a rather cheap valuation: LPCN is cheaper than 98.48% of the companies listed in the same industry.

LPCN is valuated cheaply when we compare the Price/Earnings ratio to 28.92, which is the current average of the S&P500 Index.

LPCN is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	2.11
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as LPCN's earnings are expected to decrease with -39.74% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-72.06%

EPS Next 3Y-39.74%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

LPCN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LIPOCINE INC

NASDAQ:LPCN (4/25/2025, 3:27:48 PM)

3.25

+0.07 (+2.2%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)03-13 2025-03-13/bmo

Earnings (Next)05-07 2025-05-07

Inst Owners9.16%

Inst Owner Change0%

Ins Owners2.91%

Ins Owner Change0%

Market Cap17.39M

Analysts82.86

Price Target6.89 (112%)

Short Float %1.59%

Short Ratio6.46

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)286.5%

Min EPS beat(2)17.12%

Max EPS beat(2)555.88%

EPS beat(4)4

Avg EPS beat(4)199.13%

Min EPS beat(4)17.12%

Max EPS beat(4)555.88%

EPS beat(8)5

Avg EPS beat(8)80.02%

EPS beat(12)8

Avg EPS beat(12)48.69%

EPS beat(16)12

Avg EPS beat(16)140.52%

Revenue beat(2)1

Avg Revenue beat(2)-34.53%

Min Revenue beat(2)-100%

Max Revenue beat(2)30.95%

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-32.5%

PT rev (3m)-32.5%

EPS NQ rev (1m)-9.37%

EPS NQ rev (3m)-9.37%

EPS NY rev (1m)-23.33%

EPS NY rev (3m)-51.64%

Revenue NQ rev (1m)-29.6%

Revenue NQ rev (3m)-29.6%

Revenue NY rev (1m)-20.85%

Revenue NY rev (3m)-56.37%

Valuation

		Industry Rank	Sector Rank
PE	2.11
Fwd PE	N/A
P/S	1.55
P/FCF	N/A
P/OCF	N/A
P/B	0.83
P/tB	0.83
EV/EBITDA	N/A

EPS(TTM)1.54

EY47.38%

EPS(NY)-1.89

Fwd EYN/A

FCF(TTM)-0.25

FCFYN/A

OCF(TTM)-0.23

OCFYN/A

SpS2.09

BVpS3.92

TBVpS3.92

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	0.04%
ROE	0.04%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	0.08%
GM	N/A
FCFM	N/A

ROA(3y)-33.24%

ROA(5y)-36.72%

ROE(3y)-36.81%

ROE(5y)-49.69%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.5

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	219.22%
Cap/Sales	0.8%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	14.75
Quick Ratio	14.75
Altman-Z	-4.24

F-Score5

WACC9.66%

ROIC/WACCN/A

Cap/Depr(3y)521.74%

Cap/Depr(5y)N/A

Cap/Sales(3y)9.09%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)150.49%

EPS 3Y213.46%

EPS 5YN/A

EPS Q2Q%542.86%

EPS Next Y-222.53%

EPS Next 2Y-72.06%

EPS Next 3Y-39.74%

EPS Next 5YN/A

Revenue 1Y (TTM)492.4%

Revenue growth 3Y-11.47%

Revenue growth 5Y133.89%

Sales Q2Q%1514.78%

Revenue Next Year-85.43%

Revenue Next 2Y-68.57%

Revenue Next 3Y-47.42%

Revenue Next 5Y37.92%

EBIT growth 1Y93.56%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y88.96%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y89.71%

OCF growth 3YN/A

OCF growth 5YN/A

LIPOCINE INC (LPCN) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens